NCT02124447

Brief Summary

This will be a 4-way comparison to prospectively evaluate the efficacy and patient tolerability of four commercially available bowel preparations among patients undergoing colonoscopy for screening and surveillance in a single tertiary academic medical center.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2014

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 23, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 28, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2014

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

July 10, 2015

Status Verified

July 1, 2015

Enrollment Period

2 months

First QC Date

April 23, 2014

Last Update Submit

July 9, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy of bowel cleansing according to the Boston Bowel Preparation Score (BPPS)

    Patient outcome will be assessed at the time of the colonoscopy by the performing physician and ducomentation of this outcome will occur within 24 hours of the procedure

Secondary Outcomes (1)

  • Patient tolerability and satisfaction

    Outcome of satisfaction will be assessed on a single survey that the patient will provide the day of their colonoscopy and will be recorded by study personnel up to 30 days thereafter

Study Arms (4)

PEG+E

ACTIVE COMPARATOR

Split dose 4 liter polyethylene glycol with electrolytes

Drug: PEG+E

PEG+Asc

ACTIVE COMPARATOR

Split dose 2 liter polyethylene glycol with ascorbic acid

Drug: PEG+Asc

P+MC

ACTIVE COMPARATOR

Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid

Drug: P+MC

sulfate

ACTIVE COMPARATOR

Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution

Drug: sulfate

Interventions

PEG+EDRUG

Split dose 4 liter polyethylene glycol with electrolytes

Also known as: Golytely
PEG+E

Split dose 2 liter polyethylene glycol with ascorbic acid

Also known as: MoviPrep
PEG+Asc
P+MCDRUG

Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid

Also known as: Suprep
P+MC

Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution

Also known as: Prepopik
sulfate

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or greater
  • Ability to understand and complete questionnaires
  • Ability to speak and read English
  • Willingness to participate in study
  • Colonoscopy is being performed for routine screening (i.e. no prior personal history of polyps or cancer) or surveillance (i.e. follow up for a personal history of polyps) purposes

You may not qualify if:

  • Previous bowel resection of any kind (small or large bowel)
  • End stage renal disease (ESRD)
  • Contraindication to bowel purgative
  • Necessity for inpatient admission to receive bowel preparation for any reason
  • Currently taking any narcotic/opiate pain or anticholinergic medication (since these may predispose to higher colon stool burden at baseline)
  • Currently taking stool softeners (e.g. Miralax, Amitiza, Linzess, lactulose) or stimulant laxatives (e.g. Dulcolax)
  • Subject did not follow appropriate dosing instructions for bowel purgative
  • Colonoscopy is being performed to evaluate a clinical symptom such as rectal bleeding, constipation, abdominal pain, or diarrhea
  • History of colon polyposis syndrome
  • Personal history of inflammatory bowel disease
  • History of inadequate colon preparation on any prior colonoscopies
  • Patient is pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Froedtert Hospital & The Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

MeSH Terms

Interventions

GolytelyMoviPrepSulfates

Intervention Hierarchy (Ancestors)

AnionsIonsElectrolytesInorganic ChemicalsSulfuric AcidsSulfur AcidsSulfur Compounds
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Division of Gastroenterology

Study Record Dates

First Submitted

April 23, 2014

First Posted

April 28, 2014

Study Start

June 1, 2014

Primary Completion

August 1, 2014

Study Completion

June 1, 2015

Last Updated

July 10, 2015

Record last verified: 2015-07

Locations